Rein Therapeutics (RNTX)

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

O preço da ação Rein Therapeutics, Inc. Common Stock (RNTX) pre-market hoje é de $ 1,23, refletindo uma movimentação de +2,50% pre-market desde que o mercado fechou. A capitalização de mercado da empresa é de $ 32,33 mi, com um volume comercial diário de $ 4,02 mil ações. O preço de fechamento anterior foi $ 1,20.

Vamos começar? Siga os passos abaixo ou leia nosso guia sobre como comprar Rein Therapeutics ações na Kraken a partir de US$ 10.